First National Bank of Omaha Has $15.65 Million Stake in Amgen Inc. $AMGN

Key Points

• First National Bank of Omaha cut its Amgen stake by 9.9% in the second quarter, selling 4,746 shares and retaining 43,308 shares valued at approximately $15.65 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported quarterly adjusted earnings of $6.29 per share and revenue of $10.05 billion, surpassing analyst expectations, while revenue increased 9.5% year over year. The company reaffirmed fiscal 2026 earnings guidance of $22.30–$23.50 per share.
• Amgen declared a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 payout and a 2.3% yield. Despite several analyst target increases, the consensus rating remains “Hold”, with an average price target of $379.36.

First National Bank of Omaha reduced its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,308 shares of the medical research company's stock after selling 4,746 shares during the quarter. First National Bank of Omaha's holdings in Amgen were worth $15,652,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AMGN. Brighton Jones LLC raised its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. boosted its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC boosted its holdings in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock valued at $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC grew its stake in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock valued at $15,120,000 after purchasing an additional 2,611 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ AMGN opened at $442.36 on Thursday. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $443.20. The company has a 50 day moving average of $375.75 and a 200-day moving average of $360.76. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $239.15 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 3.95 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen's revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts forecast that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen's payout ratio is presently 62.65%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent research reports. Canaccord Genuity Group increased their target price on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Scotiabank boosted their price target on Amgen from $385.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Freedom Capital upgraded Amgen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 7th. Bank of America increased their price objective on Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 5th. Finally, Daiwa Securities Group cut their price objective on Amgen from $410.00 to $390.00 and set an "outperform" rating for the company in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $379.36.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company's stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen was highlighted as one of the best-performing U.S. large-cap drugmakers in 2026, outperforming peers Merck and Pfizer despite lacking an obesity drug. The comparison reinforces investor confidence in Amgen’s existing portfolio and operating execution. Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
• Positive Sentiment: Healthcare-sector strength and a rotation toward profitable drugmakers helped lift Amgen, while renewed enthusiasm for biotechnology also improved sentiment across the industry. Amgen Stock Surges as Healthcare Hits Record High
• Positive Sentiment: Argus raised its Amgen price target from $375 to $460 and maintained a “buy” rating, citing additional upside for the shares. Argus price-target update
• Neutral Sentiment: Amgen’s latest quarterly results beat consensus estimates for earnings and revenue, with revenue growth accelerating year over year. Full-year earnings guidance and expectations for continued growth remain important supports for the investment case.
• Neutral Sentiment: The obesity-drug market is becoming more selective, and Amgen is reportedly trimming some early-stage efforts. This could improve capital discipline, but it also highlights execution risk as the company competes in a crowded field. Obesity investing’s way forward, mapped
• Negative Sentiment: Although Cantor Fitzgerald and Mizuho raised their price targets, both retained “neutral” ratings and set targets below the current trading level, signaling valuation concerns after Amgen’s strong run. Analyst price-target updates

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source